Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Weinberg & Hajcak, 2010)
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
The visceral fat deposition was also found to be reduced, along with decreased plaque macrophages and smaller aortic plaques [56]
Neumiller, J
US$ 27.48
US$ 20.71
US$ 26.51
US$ 22.93
